The drug, which Lilly has already submitted to the FDA for review, also beat Novos semaglutide at reducing A1C in a head-to-head trial for type 2 diabetes in September
doi:10.1056/NEJMoa2032183 Lempesis IG, Liu J, Dalamaga M
Gallbladder-related adverse events, including cholelithiasis and cholecystitis, have been reported more frequently in patients receiving semaglutide compared to placebo in clinical trials, with an incidence of approximately two to three percent
It potentially halts a disease trajectory
When I found MDWatch, it felt like the perfect solution
The most common side effects that showed up in trials include: Nausea, vomiting, or diarrhea Constipation Fatigue or tiredness Most of these effects were mild to moderate and tended to improve as the body adjusted